Pharmaceutical Sector

Dabur India reveals investment plan worth Rs 250 crore

Dabur India reveals investment plan worth Rs 250 croreDabur India Limited, India's leading natural healthcare company, plans to invest over Rs 250 crore in the next one year to set up a greenfield facility for manufacturing a range of consumer goods and upgrade its existing facilities.

The company plans to set up a new manufacturing facility in India entailing a capital expenditure of about Rs 150 crore, which would be made in the next fiscal.

Orchid Chemicals bags approval for Piperacillin and Tazobactam

Orchid Chemicals bags approval for Piperacillin and Tazobactam

Aurobindo Pharma Gets USFDA Nod For Ceftriaxone Injection

India’s leading drug maker, Aurobindo Pharma has got sanction from the US Aurobindo Pharma Gets USFDA Nod For Ceftriaxone Injection

Strides Arcolab completes acquisition of 50% stake in Australian firm

Drug maker Strides Arcolab has informed that it has completed acquisition of 50.1% stake in Australia stock exchange listed firm Ascent Pharmahealth, formerly known as Genepharm Australasia.

Aurobindo Pharma gets USFDA approval for Ceftriaxone Injection

Sun Pharma Still Keen On Taro Takeover

The issue between Sun Pharmaceutical Industries and Israel’s Taro Sun Pharma Still Keen On Taro Takeover  Pharmaceuticals has been in the main headlines from quite some time now. Though the former is still very keen to takeover the latter, but the legal fight between the two could delay the process. The news was broken by the Mumbai based Sun Pharma’s chairman and managing director, Dilip Shanghvi, who ruled out an out-of-court settlement with Taro Pharma.

Pages